Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Aortoiliac Occlusive Disease: Medical versus Endovascular versus Surgical Therapy

  • Vascular Disease
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion Statement

Aortoiliac occlusive disease (AIOD) is an insidious, progressive atherosclerotic process that can lead to claudication, rest pain, tissue loss, and eventual lower extremity amputation. The patient with AIOD is also at risk for both fatal and nonfatal cardiovascular events. Treatment of the disease includes both risk factor modification and efforts to improve blood flow to the lower extremity. For mild to moderate intermittent claudication, medical therapy as well as a supervised exercise program is advised. For debilitating claudication or critical limb ischemia, a number of recent studies support an endovascular approach for patients with AIOD, citing patency rates that compare favorably to open surgery. Surgical revascularization, however, should still be considered in selected patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004;110:738–43.

    Article  PubMed  Google Scholar 

  2. Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002;143:961–5.

    Article  PubMed  Google Scholar 

  3. Norgen L, Hiatt WR, Dormandy JA, et al. InterSociety Consensus for the Management of Peripheral Arterial Disease. TASC II Eur J Vasc and Endovasc Surgery. 2007;33(1):S1–S70.

    Article  Google Scholar 

  4. Raffetto JD, Montgomery JE, Eberhardt RT, LaMorte WW, Menzoian JO. Differences in risk factors for lower extremity arterial occlusive disease. J Am Coll Surg. 2005;201(6):918–24.

    Article  PubMed  Google Scholar 

  5. Aboyans V, Desormais I, Lacroix P, et al. The general prognosis of patients with peripheral arterial disease differs according to the disease localization. J Am Coll Cardiol. 2010;55(9):898–903.

    Article  PubMed  Google Scholar 

  6. Skau T, Jönsson B. Prevalence of symptomatic leg ischaemia in a Swedish community—an epidemiological study. Eur J Vasc Surg. 1993;7:432–7.

    Article  PubMed  CAS  Google Scholar 

  7. Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: Prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20:384–92.

    Article  PubMed  CAS  Google Scholar 

  8. Kannel WB, Skinner JJ, Schwartz Jr MJ, Shurtleff D. Intermittent claudication. Incidence in the Framingham Study. Circulation. 1970;41(5):875–83.

    PubMed  CAS  Google Scholar 

  9. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatric Soc. 1999;47:1255–6.

    CAS  Google Scholar 

  10. Criqui MH, Langer RD, Fronek A. Mortality over a Period of 10 Years in Patients with Peripheral Arterial Disease. N Engl J Med. 1992;326(6):381–6.

    Article  PubMed  CAS  Google Scholar 

  11. Steg PG, Bhatt DL, Wilson PW, et al. REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197–206.

    Article  PubMed  CAS  Google Scholar 

  12. Ankle Brachial Index Collaboration. Ankle Brachial Index Combined with Framingham Risk Score to Predict Cardiovascular Events and Mortality: A Meta-analysis. JAMA. 2008;300(2):197–208.

    Article  Google Scholar 

  13. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation. 2006;113(22):2623–9.

    Article  PubMed  Google Scholar 

  14. Willigendael EM, Teijink JAW, Bartelink ML, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg. 2004;40:1158–65.

    Article  PubMed  Google Scholar 

  15. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication/effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scan. 1987;221:253–60.

    Article  CAS  Google Scholar 

  16. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20, 536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45:645–54.

    Article  Google Scholar 

  17. Momsen AH, Jensen MB, Norager CB, et al. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomized controlled studies. Eur J Vasc Endovasc Surg. 2009; 38:463–474.

    Article  PubMed  CAS  Google Scholar 

  18. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med. 2000;342:145–53.

    Article  Google Scholar 

  19. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ. 2002;324:71–86.

    Article  Google Scholar 

  20. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301(18):1909–19.

    Article  PubMed  CAS  Google Scholar 

  21. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329–39.

    Article  Google Scholar 

  22. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17.

    Article  PubMed  CAS  Google Scholar 

  23. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA, CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30(2):192–201.

    Article  PubMed  CAS  Google Scholar 

  24. Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357:217–27.

    Article  Google Scholar 

  25. Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness Jr DE, Bortey EB, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159(17):2041–50.

    Article  PubMed  CAS  Google Scholar 

  26. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90(12):1314–9.

    Article  PubMed  CAS  Google Scholar 

  27. Dawson DL, Cutler BS, Meissner MH, Strandness Jr DE. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98(7):678–86.

    PubMed  CAS  Google Scholar 

  28. O’Donnell ME, Badger SA, Sharif MA, et al. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg. 2009;49(5):1226–34.

    Article  PubMed  Google Scholar 

  29. Serracino-Inglott F, Owen G, Carter A, et al. All patients benefit equally from a supervised exercise program for claudication. Vasc Endovascular Surg. 2007;41(3):212–6.

    Article  PubMed  Google Scholar 

  30. Keo H, Grob E, Guggisberg F, et al. Long-term effects of supervised exercise training on walking capacity and quality of life in patients with intermittent claudication. Vasa. 2008;37(3):250-6.

    Article  PubMed  CAS  Google Scholar 

  31. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005263.

  32. Treesak C, Kasemsup V, Treat-Jacobson D, Nyman JA, Hirsch AT. Cost-effectiveness of exercise training to improve claudication symptoms in patients with peripheral arterial disease. Vasc Med. 2004;9(4):279–85.

    Article  PubMed  Google Scholar 

  33. Greenhalgh RM, Belch JJ, Brown LC, et al. Mimic Trial Participants. The adjuvant benefit of angioplasty in patients with mild to moderate intermittent claudication (MIMIC) managed by supervised exercise, smoking cessation advice and best medical therapy: results from two randomised trials for stenotic femoropopliteal and aortoiliac arterial disease. Eur J Vasc Endovasc Surg. 2008;36(6):680-8.

    Article  PubMed  CAS  Google Scholar 

  34. Murphy TP, Hirsch AT, Ricotta JJ, et al. CLEVER investigators. The CLEVER (Claudication: Exercise Vs. Endoluminal Revascularization) Study: Rationale and Methods. J Vasc Surg. 2008;47(6):1356–63.

    Article  PubMed  Google Scholar 

  35. Caixeta A, Mehran R. Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury. Catheter Cardiovasc Interv. 2010;75 Suppl 1:S15–20.

    Article  PubMed  Google Scholar 

  36. Brown JR, Block CA, Malenka DJ, et al. Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. JACC Cardiovasc Interv. 2009;2(11):1116–24.

    Article  PubMed  Google Scholar 

  37. Upchurch GR, Dimick JB, Wainess RM, et al. Diffusion of new technology in health care: the case of aorto-iliac occlusive disease. Surgery. 2004136:812–8.

    Article  PubMed  Google Scholar 

  38. Leville CD, Kashyap VS, Clair DG, et al. Endovascular management of iliac artery occlusions: extending treatment to TransAtlantic Inter-Society Consensus class C and D patients. J Vasc Surg. 2006;43(1):32–9.

    Article  PubMed  Google Scholar 

  39. Klonaris C, Katsargyris A, Tsekouras N, et al. Primary stenting for aortic lesions: from single stenoses to total aortoiliac occlusions. J Vasc Surg. 2008;47(2):310–7.

    Article  PubMed  Google Scholar 

  40. Kashyap VS, Pavkov ML, Bena JF, et al. The management of severe aortoiliac occlusive disease: endovascular therapy rivals open reconstruction. J Vasc Surg. 2008;48(6):1451-7.

    Article  PubMed  Google Scholar 

  41. Hans SS, DeSantis D, Siddiqui R, Khoury M. Results of endovascular therapy and aortobifemoral grafting for Transatlantic Inter-Society type C and D aortoiliac occlusive disease. Surgery. 2008;144:583–90.

    Article  PubMed  Google Scholar 

  42. Burke CR, Henke PK, Hernandez R, Rectenwald JE, Krishnamurthy V, Englesbe MJ, et al. A Contemporary Comparison of Aortofemoral Bypass and Aortoiliac Stenting in the Treatment of Aortoiliac Occlusive Disease. Ann Vasc Surg. 2010;24:4–13.

    Article  PubMed  Google Scholar 

  43. Indes JE, Tuggle CT, Mandawat A, Sosa JA. Age-stratified outcomes in elderly patients undergoing open and endovascular procedures for aortoiliac occlusive disease. Surgery. 2010;148(2):420–8.

    Article  PubMed  Google Scholar 

  44. Chiu KWH, Davies RSW, Nightingale PG, Bradbury AW, Adam DJ. Review of Direct Anatomical Open Surgical Management of Atherosclerotic Aortoiliac occlusive disease. Eur J Vasc and Endovasc Surg. 2010;39:460–71.

    Article  CAS  Google Scholar 

  45. Hertzer NR, Bena JF, Karafa MT. A personal experience with direct reconstruction and extra-anatomic bypass for aortoiliofemoral occlusive disease. J Vasc Surg. 2007;45:527–35.

    Article  PubMed  Google Scholar 

  46. Janne d’Othée B, Morris MF, Powell RJ, Bettmann MA. Cost determinants of percutaneous and surgical interventions for treatment of intermittent claudication from the perspective of the hospital. Cardiovasc Intervent Radiol. 2008;31(1):56–65.

    Article  PubMed  Google Scholar 

Download references

Disclosure

Mireille Astrid Moise reports no potential conflict of interest relevant to this article. Vikram S. Kashyap reports no potential conflict of interest relevant to this article.

Author information

Authors and Affiliations

  1. Heart and Vascular Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, F30, Cleveland, OH, 44195, USA

    Mireille Astrid Moise MD & Vikram S. Kashyap MD

  2. Division of Vascular Surgery and Endovascular Therapy University Hospitals, Case Medical Center, 11100 Euclid Ave, LKS 7060, Cleveland, OH, 44106, USA

    Vikram S. Kashyap MD

Authors
  1. Mireille Astrid Moise MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vikram S. Kashyap MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vikram S. Kashyap MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moise, M.A., Kashyap, V.S. Treatment of Aortoiliac Occlusive Disease: Medical versus Endovascular versus Surgical Therapy. Curr Treat Options Cardio Med 13, 114–128 (2011). https://doi.org/10.1007/s11936-011-0117-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-011-0117-x

Keywords

Search

Navigation